TScan Therapeutics, Inc. - 8-K Filing
TScan Therapeutics reports Q3 2026 revenue of $0.6 million and net loss of $33.1 million, announcing strategic pivot to in vivo solid tumor programs. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $TCRX
Read the full article at SEC EDGAR
Part of the story enGene Therapeutics Inc. - 8-K Filing (4 articles)